Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.
Ocuphire Pharma, Inc. (OCUP) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 2.33 M | -50,501,000 | 4.04 M | 53.95 M | 53.95 M |
| 2022 | 4.85 M | -42,634,000 | 2.75 M | 48.99 M | 48.99 M |
| 2021 | -23,996,000 | 3.86 M | 26.08 M | 26.07 M | |
| 2020 | -16,399,000 | 31.15 M | 17.68 M | 17.67 M | |
| 2019 | 4.13 M | 9.34 M | 1.78 M | 1.76 M |